BR112016025196A2 - composições de oligonucleotídeo e métodos de fazê-las - Google Patents

composições de oligonucleotídeo e métodos de fazê-las

Info

Publication number
BR112016025196A2
BR112016025196A2 BR112016025196A BR112016025196A BR112016025196A2 BR 112016025196 A2 BR112016025196 A2 BR 112016025196A2 BR 112016025196 A BR112016025196 A BR 112016025196A BR 112016025196 A BR112016025196 A BR 112016025196A BR 112016025196 A2 BR112016025196 A2 BR 112016025196A2
Authority
BR
Brazil
Prior art keywords
amino group
compositions
oligonucleotide
solid phase
phosphoramidite
Prior art date
Application number
BR112016025196A
Other languages
English (en)
Other versions
BR112016025196B1 (pt
Inventor
H Ramiya Premchandran
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of BR112016025196A2 publication Critical patent/BR112016025196A2/pt
Publication of BR112016025196B1 publication Critical patent/BR112016025196B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção proporciona um método de fase sólida de fazer oligonucleotídeos através de ciclos sequenciais de acoplamento, incluindo, pelo menos, um meio de acoplamento de uma subunidade de dímero de dinucleotídeo a um grupo terminal livre em 3' de uma cadeia em crescimento. os oligonucleotídeos incluem pelo menos 2 subunidades de nucleosídeo unidas pela ligação de fosforamidato n3'¿p5'. o método pode incluir as etapas de (a) desproteção de grupo amino protegido em 3' de um nucleosídeo terminal ligado a um suporte em fase sólida, sendo que a referida desproteção forma um grupo amino em 3'; (b) contato do grupo amino livre em 3' com um dímero 5'-fosforamidita de dinucleotídeo com amino protegido em 3' na presença de um catalisador nucleofílico para formar uma ligação de fosforamidita n3'¿p5' de internucleosídeo; e (c) oxidação (p.ex. sulfuração) da ligação. as composições produzidas pelos métodos em questão podem incluir uma quantidade reduzida de um ou mais produtos de oligonucleotídeo (n-x). também são apresentadas composições farmacêuticas que incluem as composições de oligonucleotídeo em questão.
BR112016025196-2A 2014-05-01 2015-04-29 Métodos de síntese de um polinucleotídeo BR112016025196B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461987396P 2014-05-01 2014-05-01
US61/987,396 2014-05-01
US201562151909P 2015-04-23 2015-04-23
US62/151,909 2015-04-23
PCT/US2015/028327 WO2015168310A1 (en) 2014-05-01 2015-04-29 Oligonucleotide compositions and methods of making the same

Publications (2)

Publication Number Publication Date
BR112016025196A2 true BR112016025196A2 (pt) 2017-12-12
BR112016025196B1 BR112016025196B1 (pt) 2022-08-02

Family

ID=54359301

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016025196-2A BR112016025196B1 (pt) 2014-05-01 2015-04-29 Métodos de síntese de um polinucleotídeo

Country Status (32)

Country Link
US (5) US9796747B2 (pt)
EP (2) EP3137479B1 (pt)
JP (6) JP7040892B2 (pt)
KR (3) KR20210130822A (pt)
CN (3) CN111228288B (pt)
AP (1) AP2016009489A0 (pt)
AU (3) AU2015253158B2 (pt)
BR (1) BR112016025196B1 (pt)
CA (1) CA2943888A1 (pt)
CL (4) CL2016002749A1 (pt)
DK (1) DK3137479T3 (pt)
EA (1) EA034882B9 (pt)
ES (1) ES2963740T3 (pt)
FI (1) FI3137479T3 (pt)
HR (1) HRP20231505T1 (pt)
HU (1) HUE064289T2 (pt)
IL (2) IL248044B (pt)
JO (2) JOP20200257A1 (pt)
LT (1) LT3137479T (pt)
MX (2) MX2016014178A (pt)
MY (2) MY178617A (pt)
PE (1) PE20170147A1 (pt)
PH (1) PH12016502080A1 (pt)
PL (1) PL3137479T3 (pt)
PT (1) PT3137479T (pt)
RS (1) RS64860B1 (pt)
SG (2) SG11201608226YA (pt)
SI (1) SI3137479T1 (pt)
TW (2) TWI712413B (pt)
UA (1) UA126108C2 (pt)
WO (1) WO2015168310A1 (pt)
ZA (2) ZA201606624B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3296312T (lt) 2004-07-02 2021-06-10 Geron Corporation Apsaugotų 3'-amino-5'-fosforamidito nukleozido monomerų sintezė
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
TN2017000411A1 (en) 2015-04-23 2019-01-16 Geron Corp Methods of polynucleotide preparation using multivalent cation salt compositions
CA3066968C (en) * 2017-07-10 2023-06-13 Geron Corporation Improved process for preparing imetelstat
MX2022005008A (es) * 2019-10-28 2022-08-08 Geron Corp Sales de 3-(ácido graso amido)-2-hidroxi-1-(hidroxi protegido)-propano succinilada solida amorfa y métodos para elaborarlas.
AU2020375734A1 (en) 2019-10-28 2022-05-26 Geron Corporation Crystalline solids of 3-palmitoyl-amido-1,2-propanediol and 3-palmitoyl-amido-2-hydroxy-1-dimethoxytriphenylmethylether-propane and methods of making and using the same
KR20220123300A (ko) 2020-01-08 2022-09-06 닛토덴코 가부시키가이샤 분절-타입 아미디트(segment-type amidite)를 사용한 핵산 합성 방법

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046720A (en) 1974-01-17 1977-09-06 California Institute Of Technology Crosslinked, porous, polyacrylate beads
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4678814A (en) 1981-03-30 1987-07-07 California Institute Of Technology Polyacrolein microspheres
US4413070A (en) 1981-03-30 1983-11-01 California Institute Of Technology Polyacrolein microspheres
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US6448392B1 (en) 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4757141A (en) 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
WO1990010448A2 (en) 1989-03-07 1990-09-20 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US6395492B1 (en) 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6114513A (en) 1990-01-11 2000-09-05 Isis Pharmaceuticals, Inc. Thiol-derivatized oligonucleotides
AU7759291A (en) 1990-03-29 1991-10-21 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
US5420330A (en) 1990-09-07 1995-05-30 Pharmacia P-L Biochemicals Inc. Lipo-phosphoramidites
US5419966A (en) 1991-06-10 1995-05-30 Microprobe Corporation Solid support for synthesis of 3'-tailed oligonucleotides
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5837453A (en) 1992-05-13 1998-11-17 Geron Corporation Telomerase activity assays
US6235886B1 (en) 1993-09-03 2001-05-22 Isis Pharmaceuticals, Inc. Methods of synthesis and use
US5523389A (en) 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
US7067497B2 (en) 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
US6087491A (en) 1993-01-08 2000-07-11 Hybridon, Inc. Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US6350853B1 (en) 1993-04-26 2002-02-26 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
DE4331670A1 (de) 1993-09-17 1995-03-23 Hoechst Ag Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
CA2174425A1 (en) 1993-10-18 1995-04-27 Graham Leslie Barrett A method for enhancing neurone survival and agents useful for same
US5863726A (en) 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
US5726297A (en) 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
US5965720A (en) 1994-03-18 1999-10-12 Lynx Therapeutics, Inc. Oligonucleotide N3'→P5' phosphoramidates
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
GB9413035D0 (en) 1994-06-29 1994-08-17 Scras Antisense oligonucleeotides
PL181019B1 (pl) 1994-07-07 2001-05-31 Geron Corp Składnik RNA ssaczej telomerazy i sposób wytwarzania rekombinowanego enzymu telomerazy
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
WO1996014277A1 (en) 1994-11-07 1996-05-17 Hybridon, Inc. Synthesis of 35s-labeled oligonucleotides with 3h-1,2-benzodithiol-3-1,1-dioxide
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US5859233A (en) 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
GB9606158D0 (en) 1996-03-23 1996-05-29 Ciba Geigy Ag Chemical compounds
US6015710A (en) 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
WO1997037691A1 (en) 1996-04-10 1997-10-16 Lynx Therapeutics, Inc. Telomerase inhibitors
US6111085A (en) 1996-09-13 2000-08-29 Isis Pharmaceuticals, Inc. Carbamate-derivatized nucleosides and oligonucleosides
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6001991A (en) 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
US5846723A (en) 1996-12-20 1998-12-08 Geron Corporation Methods for detecting the RNA component of telomerase
CA2274586A1 (en) 1996-12-20 1998-07-02 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase
US5877309A (en) 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US5998604A (en) 1997-09-15 1999-12-07 The Perkin-Elmer Corporation Polynucleotide purification method
JP3722630B2 (ja) 1998-10-28 2005-11-30 パイオニア株式会社 記録再生装置
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
ES2302701T3 (es) 1999-09-10 2008-08-01 Geron Corporation N3'-p5' tiofosforamidatos oligonucleotidicos: su sintesis y uso.
GB9927674D0 (en) * 1999-11-23 2000-01-19 Aegis Eng Ltd Protective material
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
EP1379689B1 (en) * 2001-03-23 2012-09-26 Geron Corporation Oligonucleotide conjugates
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
EP1667522B1 (en) 2003-09-09 2018-01-17 Geron Corporation Modified oligonucleotides for telomerase inhibition
US20120329858A1 (en) * 2010-08-04 2012-12-27 Geron Corporation Modified oligonucleotides for telomerase inhibition
LT3296312T (lt) 2004-07-02 2021-06-10 Geron Corporation Apsaugotų 3'-amino-5'-fosforamidito nukleozido monomerų sintezė
WO2006023880A2 (en) * 2004-08-23 2006-03-02 Isis Pharmaceuticals, Inc. Compounds and methods for the characterization of oligonucleotides
JP2008523786A (ja) * 2004-10-18 2008-07-10 コドン デバイシズ インコーポレイテッド 高忠実度合成ポリヌクレオチドのアセンブリ方法
WO2006113470A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
US8153604B2 (en) * 2006-04-24 2012-04-10 Geron Corporation CNS-tumor treatment method and composition
DK2101789T3 (en) 2006-10-30 2015-03-23 Geron Corp Combined telomerase inhibitor and gemcitabine for the treatment of cancer
US8785409B2 (en) 2007-01-30 2014-07-22 Geron Corporation Compounds having anti-adhesive effects on cancer cells
US9106103B2 (en) 2011-09-23 2015-08-11 Eaton Corporation Unintteruptible power supply systems and methods employing on-demand energy storage
US9006630B2 (en) 2012-01-13 2015-04-14 Altasens, Inc. Quality of optically black reference pixels in CMOS iSoCs
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US20150342982A1 (en) 2012-12-07 2015-12-03 Geron Corporation Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها

Also Published As

Publication number Publication date
US10392418B2 (en) 2019-08-27
MX2016014178A (es) 2017-05-04
EP4286519A2 (en) 2023-12-06
US20180016294A1 (en) 2018-01-18
PT3137479T (pt) 2023-11-30
EA034882B9 (ru) 2020-07-13
JP2017514479A (ja) 2017-06-08
IL248044A0 (en) 2016-11-30
KR20230088509A (ko) 2023-06-19
CL2016002749A1 (es) 2017-04-28
PL3137479T3 (pl) 2024-02-26
IL268570A (en) 2019-09-26
AU2015253158B2 (en) 2019-12-12
US20220306676A1 (en) 2022-09-29
ZA202005857B (en) 2024-01-31
EA201691786A1 (ru) 2017-04-28
RS64860B1 (sr) 2023-12-29
CN111228288B (zh) 2023-10-20
AU2020201707B2 (en) 2022-02-17
JP2021182946A (ja) 2021-12-02
HUE064289T2 (hu) 2024-02-28
KR20160147768A (ko) 2016-12-23
PH12016502080A1 (en) 2017-01-09
AU2020201707A1 (en) 2020-03-26
IL268570B (en) 2021-10-31
JP2022044679A (ja) 2022-03-17
EA034882B1 (ru) 2020-04-01
PE20170147A1 (es) 2017-04-12
FI3137479T3 (fi) 2023-11-28
CL2018001212A1 (es) 2018-08-03
CL2022000202A1 (es) 2023-02-10
US11299511B2 (en) 2022-04-12
US20150337314A1 (en) 2015-11-26
ES2963740T3 (es) 2024-04-01
EP3137479B1 (en) 2023-08-30
BR112016025196B1 (pt) 2022-08-02
CA2943888A1 (en) 2015-11-05
JP2023073510A (ja) 2023-05-25
EP4286519A3 (en) 2024-02-28
JP7040892B2 (ja) 2022-03-23
EP3137479A1 (en) 2017-03-08
SG10201911086XA (en) 2020-01-30
CN111228288A (zh) 2020-06-05
TW201622732A (zh) 2016-07-01
TW202017574A (zh) 2020-05-16
NZ763996A (en) 2021-03-26
CN117357548A (zh) 2024-01-09
DK3137479T3 (da) 2023-11-20
SG11201608226YA (en) 2016-10-28
SI3137479T1 (sl) 2023-11-30
TWI712413B (zh) 2020-12-11
MY196927A (en) 2023-05-11
HRP20231505T1 (hr) 2024-03-01
TWI709406B (zh) 2020-11-11
MX2021004932A (es) 2021-08-16
WO2015168310A1 (en) 2015-11-05
CN106459134A (zh) 2017-02-22
JP2020050670A (ja) 2020-04-02
UA126108C2 (uk) 2022-08-17
EP3137479A4 (en) 2018-02-07
US9796747B2 (en) 2017-10-24
AU2015253158A1 (en) 2016-10-20
AP2016009489A0 (en) 2016-10-31
US11739114B2 (en) 2023-08-29
AU2022203273A1 (en) 2022-06-02
CL2018001213A1 (es) 2018-08-03
CN106459134B (zh) 2020-02-18
MY178617A (en) 2020-10-19
JO3767B1 (ar) 2021-01-31
JOP20200257A1 (ar) 2017-06-16
JP2018131453A (ja) 2018-08-23
US20240150391A1 (en) 2024-05-09
KR102316282B1 (ko) 2021-10-25
KR20210130822A (ko) 2021-11-01
JP7308309B2 (ja) 2023-07-13
LT3137479T (lt) 2023-10-10
ZA201606624B (en) 2020-12-23
IL248044B (en) 2019-08-29
NZ724764A (en) 2021-02-26
US20180016293A1 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
BR112016025196A2 (pt) composições de oligonucleotídeo e métodos de fazê-las
CL2016003324A1 (es) Construcciones de anticuerpos multiespecificos.
EA201490993A1 (ru) МОДИФИЦИРОВАННЫЕ СРЕДСТВА РНКи
PH12018500145A1 (en) Oligonucleotide compositions and methods thereof
CL2017003163A1 (es) Nuevos derivados aminoácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
BR112017024770A2 (pt) polipeptídeos inovadores
BR112016016400A2 (pt) Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
WO2016160844A3 (en) Methods and compositions for combinatorial barcoding
EA201692535A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
EA201690526A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
BR112017016681A2 (pt) vetor de coexpressão de vacina e moléculas coestimulatórias
EA201690274A1 (ru) Способ сайт-специфического ферментативного мечения нуклеиновых кислот in vitro введением не встречающихся в природе нуклеотидов
CL2013003053A1 (es) Compuesto que comprende un oligonucleotido modificado que consiste en de 10 a 30 nucleósidos unidos y definidos por un grupo de secuencias específicas; composicion que comprende dicho compuesto; uso para tratar enfermedades relacionadas con el virus de la hepatitis b (vhb).
EA201690492A1 (ru) Проникающие в клетку конъюгаты и способы их применения
WO2014011753A3 (en) Anthraquinone analogs and methods of making and using thereof
BR112016015701A2 (pt) Dendrímero de peptídeo, método de esterilização do mesmo, composição, composição farmacêutica, método de polimerização de fibrinogênio, kit para formação de um hidrogel e hidrogel
BR112012018343A2 (pt) "composições imunogênicas"
CO2017009217A2 (es) Métodos de preparación de polinucleótidos de tiofosforamidato n3’→p5’ usando composiciones salinas de cationes multivalentes
WO2012082753A3 (en) Polymerization of nucleic acids using activation by polyphosphorolysis (app) reactions
AR086925A1 (es) Metodos, composiciones y kits para determinar el virus de la inmunodeficiencia humana (vih)
TH166778B (th) องค์ประกอบโอลิโกนิวคลีโอไทด์และวิธีการในการทำองค์ประกอบนี้
AR100235A1 (es) Composiciones de oligonucleótidos y métodos para realizarlas
EA202090282A1 (ru) Композиции олигонуклеотидов и способы их получения
TH166778A (th) องค์ประกอบโอลิโกนิวคลีโอไทด์และวิธีการในการทำองค์ประกอบนี้
AR105066A1 (es) Enzimas y sistemas crispr

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25G Requested change of headquarter approved

Owner name: GERON CORPORATION (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/04/2015, OBSERVADAS AS CONDICOES LEGAIS